Replies to post #38344 on Amarin Corp Plc (AMRN)

[zumantu]

There has to be an inflection point from higher than expected efficacy if reached before interim would make DMC scratch their heads and consider possibility that Vascepa is working so well the safety concern are the subjects in placebo arm
I realize it's a high bar, but there has to be a bar

[James364202]

HD, I believe "safety data" would include facts like if 40% more patients in controll had CVE. It would be unethical to continue study.